Navigation Links
Inimex Product Candidate is First Immune Defense Regulator to Cure,Infections Without Causing Harmful Inflammation

Novel Approach to Address Growing Problem of Antibiotic Resistance Published in Nature Biotechnology

VANCOUVER, British Columbia, March 26, 2007 /PRNewswire/ -- Inimex Pharmaceuticals Inc.'s product candidate IDR-1 is the first immune system trigger to cure infections without causing harmful inflammation, according to a paper published in the April 2007 issue of Nature Biotechnology.

The paper, which highlights the work of Inimex and its co-founders Dr. Bob Hancock and Dr. Brett Finlay, shows that IDR-1 protected mice against Methicillin Resistant Staphylococcus (MRSA) and Vancomycin Resistant Enterococcus (VRE) infections. With as little as one dose, IDR-1 increased the levels of key immune system fighter cells, which caused prolonged enhancement of the host immune system's response to these antibiotic-resistant pathogens. A key finding was that the product eradicated the infections without increasing the levels of pro-inflammatory cytokines that are typically present during the first stage of immunity.

"The body's immune system naturally possesses the tools to fight infections," said John North, president and chief executive officer of Inimex. "We're developing therapeutics that utilize this powerful innate response without the threat of a cytokine storm that can lead to sepsis."

Bob Hancock added: "The success of our product in controlling bacterial infection represents a novel approach at a time when antibiotic resistance is getting worse every day. With the decline of new antibiotic discovery, we desperately need new avenues of research for the treatment of super bugs."

Methicillin Resistant Staphylococcus (MRSA) and Vancomycin Resistant Enterococcus (VRE) cause infections that antibiotics can no longer treat and account for more than 90,000 deaths each year in North America alone. Inimex's goal is to develop IDR products as a new line of defense against pathogens that seek out residents of hospital and treatment centers whose immune systems are battered by age, disease or myelosuppressive medications.

The paper was published as Scott, M.G. et al. (2007) "An anti-infective peptide that selectively modulates the innate immune response" in Nature Biotechnology (April 2007, vol. 25 No. 4) and will be accessible online on March 25.

About Inimex Pharmaceuticals

Inimex Pharmaceuticals Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), novel first-in-class drugs that selectively trigger the body's innate defenses without causing inflammation. IDRs have major market potential for infectious diseases, cancer and inflammatory disease. Inimex's investors include BDC Venture Capital, Canadian Medical Discovery Fund, Growthworks Capital, Discovery Capital and BC Advantage Fund. For more information, visit http://www.inimexpharma.com.

    Noonan Russo

    Andrew Villani or David Schull

    212-845-4262

    

    

andrew.villani@eurorscg.com david.schull@eurorscg.com

CONTACT: Andrew Villani, , or David Schull,, both of Noonan Russo, +1-212-845-4262, forInimex Pharmaceuticals Inc. andrew.villani@eurorscg.com david.schull@eurorscg.com

Web site: http://www.inimexpharma.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
2. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
3. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
4. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
5. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
6. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
7. PromegaExpress Expands Easy Access to Products with New Cabinet
8. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
9. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
10. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... CLEMENTE, Calif. , June 24, 2016  American Respiratory Labs ... company, is now able to perform sophisticated lung assessments in patients, ... Technologies , Inc. Patients are no longer limited ... ndd,s EasyOne PRO ® , ARL patients like Jeanne R. of ... done in the comfort of her own home. ...
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 27, 2016 , ... TherapySites, the leading website ... Tennessee Counseling Association. This new relationship allows TherapySites to continue to ... adding exclusive benefits and promotional offers. , "TCA is extremely excited about this ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever ... Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation ... as home to some of the world’s leading providers of cereal and other breakfast ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
Breaking Medicine News(10 mins):